TGA approves new medicine for basal cell carcinoma

TGA

29 July 2020 - Cemiplimab (Libtayo) has been provisionally registered by the TGA.

Libtayo as monotherapy has provisional approval for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Cemiplimab is a fully human immunoglobulin G4 monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2).

Read TGA News


Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Australia